

Amendment to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application:

Claims 1-10. (Canceled) .

11. (Currently amended) A method of preventing influenza, comprising a step of administering to nasal mucosa at least once:

A) a vaccine at a concentration sufficient to produce secretory IgA, wherein said vaccine comprises for mucosal administration comprising:

- a) a double-stranded RNA;
- b) a subunit antigen or inactivated antigen of an influenza virus; and
- c) a pharmaceutically acceptable carrier, wherein said carrier is selected from the group consisting of water, or a an aqueous physiological solution, and [[or]] an artificial aqueous cerebrospinal fluid.

12. (Original) The method of claim 11, wherein said vaccine is administered at least twice.

13. (Original) The method of claim 11, wherein said vaccine is administered at an interval of at least 1 week or more.

14. (Original) The method of claim 11, wherein said double-stranded RNA comprises Poly(I:C).

Claims 15-22. (Canceled).